Teramo Advisors’s Pfizer PFE Stock Holding History

Teramo Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,000	Closed	-$257K	–	18
2023 Q2	$257K	Buy	+7,000	New	+$272K	0.11%	15

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Teramo Advisors's PFE Position: Q2 2022 in Review

Teramo Advisors sold out of Pfizer (PFE) in Q2 2022, closing a stake of 4,000 shares — an estimated $207K sold.

Teramo Advisors first reported a position in PFE in Q4 2021 and held it in 2 quarters. The position peaked at $236K in Q4 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

Teramo Advisors reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
Teramo Advisors sold 4,000 Pfizer shares in Q2 2022, an estimated $207K.
Teramo Advisors first reported a position in Pfizer in Q4 2021 and held it in 2 quarters.
Teramo Advisors's Pfizer position peaked at $236K in Q4 2021.
3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Teramo Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.